Skip to main content
. 2023 Jun 30;13:1134646. doi: 10.3389/fonc.2023.1134646

Table 1.

Baseline clinical characteristics of the training and validation sets.

Characteristic Total (n = 185) Training set (n = 124) Validation set (n = 61) p value
Age (years) 45 [42, 67] 56 [50, 68] 56 [45, 65] 0.264
Sex (male) 168 (90.8%) 110 (88.7%) 58 (95.1%) 0.511
HBsAg 0.081
Negative 30 (16.2%) 17(13.7%) 13 (21.3%)
Positive 155 (83.8%) 107 (86.3%) 48 (78.7%)
ALT (U/L) 31.00 [22.50, 51.00] 36.00 [21.50, 57.35] 32.50 [22.50, 54.00] 0.677
AST (U/L) 40.50 [24.50, 45.55] 40.00 [24.00, 46.50] 42.50 [22.00, 55.75] 0.846
GGT (U/L) 55.00 [38.50, 108.65] 52.00 [35.50, 106.25] 53.70 [32.45, 125.50] 0.613
ALP (U/L) 82.50 [68.55, 102.50] 81.00 [70.00, 106.00] 85.00 [67.50, 108.55] 0.327
ALB (g/L) 40.35 [35.30, 43.47] 38.80 [37.58, 42.25] 36.50 [35.50, 42.70] 0.162
TBIL (µmol/L) 14.62 [12.00, 16.32] 13.62 [10.34, 16.56] 14.50 [12.60, 18.61] 0.665
SCr (U/L) 75.20 [66.15, 87.50] 75.60 [67.00, 86.85] 76.00 [68.28, 87.30] 0.548
PT (s) 11.60 [11.40, 12.50] 11.80 [11.60, 12.60] 11.95 [11.40, 12.58] 0.756
INR 0.673
≤1.0 76 (41.1%) 49 (39.5%) 27 (44.3%)
>1.0 109 (58.9%) 75 (60.5%) 34 (55.7%)
NLR 2.01 [1.44, 3.45] 2.43 [1.83, 3.42] 2.05 [1.58, 3.72] 0.403
PLR 103.45 [70.55, 148.65] 112.96 [83.15, 144.27] 102.83 [71.30, 156.22] 0.761
AFP (ng/mL) 24.35 [4.24, 132.41] 18.55 [7.39, 92.32] 28.53 [5.53, 545.00] 0.206

Continuous variables are presented as median [inter-quartile range, IQR]. Categorial variables are presented as number (percentage). p-values represent the result of comparison of the training set with the test set.

HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, glutamyl transpeptidase; ALP, alkaline phosphatase; ALB, albumin; TBIL, total bilirubin; SCr, serum creatinine; PT, prothrombin time; INR, international normalized ratio; NLR, neutrophil to Lymphocyte ratio; PLR, platelet to Lymphocyte ratio; AFP, alpha fetoprotein.